Noe Macias-Segura

Noe Macias-Segura

Auto-generated profile, based on publicly available information

Noe Macias-Segura

Unidad de Investigación Biomédica de Zacatecas, IMSS, Zacatecas, México; Laboratorio de Neuroinmunoendocrinología, Departamento de Fisiología y Farmacología, Centro de Ciencias Básicas, Universidad Autónoma de Aguascalientes, México

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
JCJulio E. Castañeda-Delgado
Julio E. Castañeda-Delgado
YBYadira Bastián-Hernandez
Yadira Bastián-Hernandez
NMNoe Macias-Segura
Noe Macias-Segura
DSDavid Santiago-Algarra
David Santiago-Algarra
JCJose D. Castillo-Ortiz
Jose D. Castillo-Ortiz
JMJosé Antonio Antonio Enciso Moreno
José Antonio Antonio Enciso Moreno
Rheumatoid arthritis is an inflammatory debilitating disease that affects the joints in the early and productive phases of an individual’s life. Several cytokines have been linked to the disease pathogenesis and are known to contribute to the inflammatory state characteristic of RA. The participation of type I interferon (IFN) in the pathogenesis of the disease has been already described as well as the identity of the genes that are regulated by this molecule, which are collectively known as the type I IFN signature. These genes have several functions associated to apoptosis, transcriptional regulation, protein degradation, Th2 cell induction, B cell proliferation, etc. The present article evaluates the expression of the IFN signature in different stages of disease and their correlation with the levels of antibodies against citrullinated proteins (ACPA) and carbamylated proteins (Anti-CarP). Methods: Samples from individuals with early and established RA, high risk individuals (ACPA+ and ACPA-) and healthy controls were recruited at “Unidad de Artritis y Rheumatismo” (Rheumatism and Arthritis Unit) in Guadalajara Jalisco Mexico. Determinations of ACPA were made with Eurodiagnostica ACPA plus kit. Anti-CarP determinations were made according to previously described protocols. RNA was isolated and purity and integrity determined according to RIN > 6. Gene expression analysis was made by RT-qPCR using specific primers for mRNAs of the type I IFN signature. Relative gene expression was calculated according to (Livak and Schmitgen). Results: Significant differences in gene expression were identified when comparing the different groups for MXA and MXB (p<0.05), also when comparing established RA and ACPA- in both IFIT 1 and G15. Increased expression of ISG15 was identified (p<0.05) and a clear tendency toward increase was identified for HERC5. EPSTRI1, IFI6 and IFI35 were found to be elevated in the cRA and eRA respectively (p<0.05). Significant correlations were identified for the IFN signature genes with the levels of ACPA and Anti-CarP (p<0.05). Conclusion: Our data confirms previous observations in the role of IFN signature and the pathogenesis of RA. Also, we provide evidence of an association between IFN-signature genes (that regulate Th2 cells and B cell proliferation) with the levels Anti-CarP and ACPA autoantibodies.

1 August 2011 in Human Immunology
Verified
Journal Article
Closed access
IGIrma González-Curiel
Irma González-Curiel
JDJulio Enrique Delgado
Julio Enrique Delgado
NLNallely Lopez-Lopez
Nallely Lopez-Lopez
ZAZaida Araujo
Zaida Araujo
Rogelio Hernández-PandoRogelio Hernández-Pando
Rogelio Hernández-Pando
BRBruno Rivas-Santiago
Bruno Rivas-Santiago

1 April 2015 in Archives of Medical Research
Verified
Journal Article
Closed access
GMGerardo Martínez-Aguilar
Gerardo Martínez-Aguilar
CSCarmen J. Serrano
Carmen J. Serrano
JDJulio Enrique Delgado
Julio Enrique Delgado
NMNoé Macías-Segura
Noé Macías-Segura
NHNicolás Hernández-Delgadillo
Nicolás Hernández-Delgadillo
JEJosé Antonio Enciso-Moreno
José Antonio Enciso-Moreno

1 December 2019 in Gene
Verified
Journal Article
Closed access
MRM.F. Romo-García
M.F. Romo-García
YBY. Bastian
Y. Bastian
MZM. Zapata-Zuñiga
M. Zapata-Zuñiga
NMN. Macías-Segura
N. Macías-Segura
JCJ.D. Castillo-Ortiz
J.D. Castillo-Ortiz
JDJulio Enrique Delgado
Julio Enrique Delgado

27 March 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NMN. Macías-Segura
N. Macías-Segura
JDJulio Enrique Delgado
Julio Enrique Delgado
YBY. Bastian
Y. Bastian
DSD. Santiago-Algarra
D. Santiago-Algarra
JCJ. D. Castillo-Ortiz
J. D. Castillo-Ortiz
JMJosé Antonio Antonio Enciso Moreno
José Antonio Antonio Enciso Moreno
Little is known regarding the mechanisms underlying the loss of tolerance in the early and preclinical stages of autoimmune diseases. The aim of this work was to identify the transcriptional profile and signaling pathways associated to non-treated early rheumatoid arthritis (RA) and subjects at high risk. Several biomarker candidates for early RA are proposed. Whole blood total RNA was obtained from non-treated early RA patients with 0.92. These genes come from several functional categories associated to inflammation, Wnt signaling and type I interferon pathways. The presence of a specific transcriptome in whole blood of RA patients suggests the activation of a specific inflammatory transcriptional signature in early RA development. The set of overexpressed genes in early RA patients that are shared with ACCP+ subjects but not with ACCP- subjects, can represent a transcriptional signature involved with the transition of a preclinical to a clinical RA stage. Some of these particular up-regulated and down-regulated genes are related to inflammatory processes and could be considered as biomarker candidates for disease progression in subjects at risk to develop RA.

1 January 2016 in Clinical Immunology
Verified
Journal Article
Closed access
CSCarmen J. Serrano
Carmen J. Serrano
BCBetzaida Cuevas-Córdoba
Betzaida Cuevas-Córdoba
NMNoé Macías-Segura
Noé Macías-Segura
RGRosa Angélica González-Curiel
Rosa Angélica González-Curiel
VMVíctor Yordani Martínez-Balderas
Víctor Yordani Martínez-Balderas
JMJosé Antonio Antonio Enciso Moreno
José Antonio Antonio Enciso Moreno